A Prospective Clinical Cohort Study on Stratified Treatment of Rhabdomyosarcoma Based on Risk Factors.

Launched by YIZHUO ZHANG · Feb 15, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for a type of pediatric cancer called rhabdomyosarcoma, which primarily affects children and young adults. Researchers want to find out how effective and safe a specific treatment plan, known as SYSUCC-RMS, is when combined with radiotherapy (a type of cancer treatment using high-energy rays) for children diagnosed with this cancer. They are particularly interested in how well this treatment works for patients with different levels of risk: low, medium, high, and extremely high.

To participate in the trial, children aged from newborn to 17 years old who have just been diagnosed with rhabdomyosarcoma may be eligible. Important criteria include having a good expected survival time of more than eight months and their parents or guardians needing to give permission for them to join. The trial is currently recruiting participants, and those who take part can expect to receive close monitoring and care throughout the study. This research could help improve treatment options for future patients with rhabdomyosarcoma.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. 0 years \< age \< 18 years old, regardless of gender;
• • 2. Tumor patients diagnosed by histopathology or bone marrow cytology;
• • 3. Patients are treated for the first time;
• • 4. ECoG score ≤ 2;
• • 5. The expected survival time is more than 8 months;
• • 6. Patient's parent or guardian signs informed consent.
• Exclusion Criteria:
• • 1. Combined with immunodeficiency disease
• • 2. Second tumor